Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Above 200 Day Moving Average of $1.09

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.09 and traded as high as $1.21. Bolt Biotherapeutics shares last traded at $1.19, with a volume of 154,904 shares traded.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Bolt Biotherapeutics in a report on Friday, March 22nd.

Bolt Biotherapeutics Stock Up 7.2 %

The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.17 and a current ratio of 5.17. The firm has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.09. The company has a market capitalization of $45.37 million, a PE ratio of -0.65 and a beta of 0.99.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Thursday, March 21st. The company reported ($0.47) EPS for the quarter, hitting the consensus estimate of ($0.47). The company had revenue of $2.09 million during the quarter, compared to analyst estimates of $1.97 million. Bolt Biotherapeutics had a negative return on equity of 51.18% and a negative net margin of 878.58%. Equities research analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Newtyn Management LLC lifted its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 2.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,020,000 shares of the company’s stock after buying an additional 20,000 shares during the period. Newtyn Management LLC owned approximately 2.69% of Bolt Biotherapeutics worth $1,061,000 at the end of the most recent reporting period. 86.70% of the stock is owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.